The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Reaching for high-hanging fruit in drug discovery at protein–protein interfaces
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
The Bcl-2 Protein Family: Arbiters of Cell Survival
Adams, J. M., & Cory, S. (1998) · Science · doi:10.1126/science.281.5381.1322 · Cited by 5,332
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · cited 1×
“2 ; Table 1 ), was found to disrupt HDM2–p53 complexes with an IC 50 of 90 nM, and it showed potent p53-blocking activity in vitro and activity against tumour xenografts in vivo”
BackgroundDrug-like properties and the causes of poor solubility and poor permeability
Lipinski, C. A. (2000) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00107-6 · Cited by 3,734
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,416
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305
Global landscape of protein complexes in the yeast Saccharomyces cerevisiae
Krogan, N. J., Cagney, G., Yu, H., Zhong, G., Guo, X., Ignatchenko, A., Li, J., Pu, S., Datta, N., Tikuisis, A. P., et al. (2006) · Nature · doi:10.1038/nature04670 · Cited by 2,952
Principles of protein-protein interactions
Jones, S., & Thornton, J. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.1.13 · Cited by 2,684
Relating protein pharmacology by ligand chemistry
Keiser, M. J., Roth, B. L., Armbruster, B. N., Ernsberger, P., Irwin, J. J., & Shoichet, B. K. (2007) · Nature Biotechnology · doi:10.1038/nbt1284 · Cited by 2,402
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
Cited by
The re-emergence of natural products for drug discovery in the genomics era
Harvey, A. L., Edrada-Ebel, R., & Quinn, R. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4510 · Cited by 2,572
Molecular Docking and Structure-Based Drug Design Strategies
Ferreira, L., Dos Santos, R., Oliva, G., & Andricopulo, A. (2015) · Molecules · doi:10.3390/molecules200713384 · Cited by 2,528
Click Chemistry for Drug Development and Diverse Chemical–Biology Applications
Thirumurugan, P., Matosiuk, D., & Jozwiak, K. (2013) · Chemical Reviews · doi:10.1021/cr200409f · Cited by 1,896
Principles of cancer therapy: oncogene and non-oncogene addiction
Luo, J., Solimini, N. L., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.02.024 · Cited by 1,765
Improved Docking of Polypeptides with Glide
Tubert-Brohman, I., Sherman, W., Repasky, M., & Beuming, T. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci400128m · Cited by 1,308
MDM2, MDMX and p53 in oncogenesis and cancer therapy
Wade, M., Li, Y.-C., & Wahl, G. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3430 · Cited by 1,279
Electrostatic Interactions in Protein Structure, Folding, Binding, and Condensation
Zhou, H.-X., & Pang, X. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00305 · Cited by 1,190
Identification of direct residue contacts in protein–protein interaction by message passing
Weigt, M., White, R. A., Szurmant, H., Hoch, J. A., & Hwa, T. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805923106 · Cited by 1,025
Small molecules, big targets: drug discovery faces the protein–protein interaction challenge
Scott, D. E., Bayly, A. R., Abell, C., & Skidmore, J. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.29 · Cited by 1,137
Small-Molecule Inhibitors of Protein-Protein Interactions: Progressing toward the Reality
Arkin, M. R., Tang, Y., & Wells, J. A. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.09.001 · Cited by 1,065
Self-citationLu, H., Zhou, Q., He, J., Jiang, Z., Peng, C., Tong, R., & Shi, J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00315-3 · Cited by 891
“It has been used to identify compounds that target the hot-spots of PPI interfaces.(16) Because of the particularity of PPI interface, the compound library used for screening conventional targets may not be suitable for screening PPI modulators.”
MethodCell cycle kinases as therapeutic targets for cancer
Lapenna, S., & Giordano, A. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2907 · Cited by 905
Structure and dynamics of molecular networks: A novel paradigm of drug discovery
Csermely, P., Korcsmáros, T., Kiss, H. J. M., London, G., & Nussinov, R. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.016 · Cited by 892
SLC6 Neurotransmitter Transporters: Structure, Function, and Regulation
Kristensen, A. S., Andersen, J., Jørgensen, T. N., Sørensen, L., Eriksen, J., Loland, C. J., Strømgaard, K., & Gether, U. (2011) · Pharmacological Reviews · doi:10.1124/pr.108.000869 · Cited by 864
Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?
Vigil, D., Cherfils, J., Rossman, K. L., & Der, C. J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2960 · Cited by 819
The rise of fragment-based drug discovery
Murray, C. W., & Rees, D. C. (2009) · Nature Chemistry · doi:10.1038/nchem.217 · Cited by 791
Advances in targeting cyclic nucleotide phosphodiesterases
Maurice, D. H., Ke, H., Ahmad, F., Wang, Y., Chung, J., & Manganiello, V. C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4228 · Cited by 776
Inhibition of α-helix-mediated protein–protein interactions using designed molecules
Azzarito, V., Long, K., Murphy, N. S., & Wilson, A. J. (2013) · Nature Chemistry · doi:10.1038/nchem.1568 · Cited by 727
Novel trends in high-throughput screening
Mayr, L. M., & Bojanic, D. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.08.004 · Cited by 694
A Comprehensive Review on Current Advances in Peptide Drug Development and Design
Lee, A. C.-L., Harris, J. L., Khanna, K. K., & Hong, J.-H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102383 · Cited by 686
The unfoldomics decade: an update on intrinsically disordered proteins
Dunker, A. K., Oldfield, C. J., Meng, J., Romero, P., Yang, J. Y., Chen, J., Vacic, V., Obradovic, Z., & Uversky, V. N. (2008) · BMC Genomics · doi:10.1186/1471-2164-9-s2-s1 · Cited by 670
Small‐Molecule PROTACS: New Approaches to Protein Degradation
Toure, M., & Crews, C. M. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201507978 · Cited by 674
Multifaceted Roles of Disulfide Bonds. Peptides as Therapeutics
Góngora-Benítez, M., Tulla-Puche, J., & Albericio, F. (2014) · Chemical Reviews · doi:10.1021/cr400031z · Cited by 655
Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design
Ostrem, J. M. L., & Shokat, K. M. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.139 · Cited by 641
Recent Developments in Fragment-Based Drug Discovery
Congreve, M., Chessari, G., Tisi, D., & Woodhead, A. J. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8000373 · Cited by 611
Buckley, D. L., Van Molle, I., Gareiss, P. C., Tae, H. S., Michel, J., Noblin, D. J., Jorgensen, W. L., Ciulli, A., & Crews, C. M. (2012) · Journal of the American Chemical Society · doi:10.1021/ja209924v · Cited by 569
Protein structure-based drug design: from docking to molecular dynamics
Śledź, P., & Caflisch, A. (2018) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2017.10.010 · Cited by 565
Spray drying formulation of amorphous solid dispersions
Singh, A., & Van den Mooter, G. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.12.010 · Cited by 526
On the binding affinity of macromolecular interactions: daring to ask why proteins interact
Kastritis, P. L., & Bonvin, A. M. J. J. (2013) · Journal of The Royal Society Interface · doi:10.1098/rsif.2012.0835 · Cited by 520
Modulators of Protein–Protein Interactions
Milroy, L.-G., Grossmann, T. N., Hennig, S., Brunsveld, L., & Ottmann, C. (2014) · Chemical Reviews · doi:10.1021/cr400698c · Cited by 497
N‐Methylation of Peptides and Proteins: An Important Element for Modulating Biological Functions
Chatterjee, J., Rechenmacher, F., & Kessler, H. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201205674 · Cited by 494
Bridging solubility between drug discovery and development
Di, L., Fish, P. V., & Mano, T. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2011.11.007 · Cited by 491
NanoBRET—A Novel BRET Platform for the Analysis of Protein–Protein Interactions
Machleidt, T., Woodroofe, C. C., Schwinn, M. K., Méndez, J., Robers, M. B., Zimmerman, K., Otto, P., Daniels, D. L., Kirkland, T. A., & Wood, K. V. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00143 · Cited by 491
Ligand and Target Discovery by Fragment-Based Screening in Human Cells
Parker, C. G., Galmozzi, A., Wang, Y., Correia, B. E., Sasaki, K., Joslyn, C. M., Kim, A. S., Cavallaro, C. L., Lawrence, R. M., Johnson, S. R., et al. (2017) · Cell · doi:10.1016/j.cell.2016.12.029 · Cited by 439
Diversity-oriented synthesis: producing chemical tools for dissecting biology
O' Connor, C. J., Beckmann, H. S. G., & Spring, D. R. (2012) · Chemical Society Reviews · doi:10.1039/c2cs35023h · Cited by 434
An Aggregation Advisor for Ligand Discovery
Irwin, J. J., Duan, D., Torosyan, H., Doak, A. K., Ziebart, K. T., Sterling, T., Tumanian, G., & Shoichet, B. K. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01105 · Cited by 418
Small-Molecule Inhibition of BRDT for Male Contraception
Matzuk, M. M., McKeown, M. R., Filippakopoulos, P., Li, Q., Ma, L., Agno, J. E., Lemieux, M. E., Picaud, S., Yu, R. N., Qi, J., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.045 · Cited by 416
Targeted Protein Degradation: from Chemical Biology to Drug Discovery
Cromm, P. M., & Crews, C. M. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.05.024 · Cited by 412
Targeting protein–protein interactions as an anticancer strategy
Ivanov, A. A., Khuri, F. R., & Fu, H. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.04.007 · Cited by 401
“Recent studies have addressed some of these concerns as detailed in several publications [1, 9, 10].”
BackgroundMethodInfluentialVillar, E. A., Beglov, D., Chennamadhavuni, S., Porco, J. A., Kozakov, D., Vajda, S., & Whitty, A. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1584 · Cited by 400
Galdeano, C., Gadd, M. S., Soares, P., Scaffidi, S., Van Molle, I., Birced, I., Hewitt, S., Dias, D. M., & Ciulli, A. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5011258 · Cited by 399
Protein–protein interaction and quaternary structure
Janin, J., Bahadur, R. P., & Chakrabarti, P. (2008) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583508004708 · Cited by 398
How viruses hijack cell regulation
Davey, N. E., Travé, G., & Gibson, T. J. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2010.10.002 · Cited by 393
What Do Medicinal Chemists Actually Make? A 50-Year Retrospective
Walters, W. P., Green, J., Weiss, J. R., & Murcko, M. A. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200504p · Cited by 387
Theory of Free Energy and Entropy in Noncovalent Binding
Zhou, H.-X., & Gilson, M. K. (2009) · Chemical Reviews · doi:10.1021/cr800551w · Cited by 385
Structure-guided design of a selective BCL-XL inhibitor
Lessene, G., Czabotar, P. E., Sleebs, B. E., Zobel, K., Lowes, K. N., Adams, J. M., Baell, J. B., Colman, P. M., Deshayes, K., Fairbrother, W. J., et al. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1246 · Cited by 381
Combining supramolecular chemistry with biology
Uhlenheuer, D. A., Petkau, K., & Brunsveld, L. (2010) · Chemical Society Reviews · doi:10.1039/b820283b · Cited by 377
Predicting Protein–Protein Interactions from the Molecular to the Proteome Level
Keskin, O., Tuncbag, N., & Gursoy, A. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00683 · Cited by 369
G protein βγ subunits: Central mediators of G protein-coupled receptor signaling
Smrcka, A. V. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8006-5 · Cited by 365
Hetrick, B., Han, M. S., Helgeson, L. A., & Nolen, B. J. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.03.019 · Cited by 353
Cross-Linking Mass Spectrometry: An Emerging Technology for Interactomics and Structural Biology
Yu, C., & Huang, L. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.7b04431 · Cited by 353
Peptide therapeutics: Targeting the undruggable space
Tsomaia, N. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.01.014 · Cited by 348
PROTAC Technology: Opportunities and Challenges
Gao, H., Sun, X., & Rao, Y. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00597 · Cited by 345
HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs?
Simões-Pires, C., Zwick, V., Nurisso, A., Schenker, E., Carrupt, P.-A., & Cuendet, M. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-7 · Cited by 341
Drugging Membrane Protein Interactions
Yin, H., & Flynn, A. D. (2016) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-092115-025322 · Cited by 339
Computer-Aided Drug Design and Drug Discovery: A Prospective Analysis
Niazi, S. K., & Mariam, Z. (2023) · Pharmaceuticals · doi:10.3390/ph17010022 · Cited by 336
The 'rule of three' for fragment-based drug discovery: where are we now?
Jhoti, H., Williams, G., Rees, D. C., & Murray, C. W. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3926-c1 · Cited by 328
β-Hairpin Peptidomimetics: Design, Structures and Biological Activities
Robinson, J. A. (2008) · Accounts of Chemical Research · doi:10.1021/ar700259k · Cited by 321
Allosteric inhibition of hypoxia inducible factor-2 with small molecules
Scheuermann, T. H., Li, Q., Ma, H.-W., Key, J., Zhang, L., Chen, R., Garcia, J. A., Naidoo, J., Longgood, J., Frantz, D. E., et al. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1185 · Cited by 315
Oncogenic protein interfaces: small molecules, big challenges
Nero, T. L., Morton, C. J., Holien, J. K., Wielens, J., & Parker, M. W. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3690 · Cited by 312
Predicting druggable binding sites at the protein–protein interface
Fuller, J. C., Burgoyne, N. J., & Jackson, R. M. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2008.10.009 · Cited by 310
Molecular Shape and Medicinal Chemistry: A Perspective
Nicholls, A., McGaughey, G. B., Sheridan, R. P., Good, A. C., Warren, G., Mathieu, M., Muchmore, S. W., Brown, S. P., Grant, J. A., Haigh, J. A., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm900818s · Cited by 310
History of protein–protein interactions: From egg‐white to complex networks
Braun, P., & Gingras, A. (2012) · PROTEOMICS · doi:10.1002/pmic.201100563 · Cited by 308
Intrinsically disordered proteins are potential drug targets
Metallo, S. J. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.06.169 · Cited by 303
Small‐Molecule Inhibitors of the Interaction between the E3 Ligase VHL and HIF1α
Buckley, D. L., Gustafson, J. L., Van Molle, I., Roth, A. G., Tae, H. S., Gareiss, P. C., Jorgensen, W. L., Ciulli, A., & Crews, C. M. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201206231 · Cited by 302
Sun, D., Li, Z., Rew, Y., Gribble, M., Bartberger, M. D., Beck, H. P., Canon, J., Chen, A., Chen, X., Chow, D., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401753e · Cited by 290
Modulating protein–protein interactions: the potential of peptides
Nevola, L., & Giralt, E. (2015) · Chemical Communications · doi:10.1039/c4cc08565e · Cited by 289
Choose your partners: dimerization in eukaryotic transcription factors
Amoutzias, G. D., Robertson, D. L., Van de Peer, Y., & Oliver, S. G. (2008) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2008.02.002 · Cited by 289
A Small-Molecule Inhibitor of BCL6 Kills DLBCL Cells In Vitro and In Vivo
Cerchietti, L. C., Ghetu, A. F., Zhu, X., Da Silva, G. F., Zhong, S., Matthews, M., Bunting, K. L., Polo, J. M., Farès, C., Arrowsmith, C. H., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.050 · Cited by 288
Pathological Unfoldomics of Uncontrolled Chaos: Intrinsically Disordered Proteins and Human Diseases
Uversky, V. N., Davé, V., Iakoucheva, L. M., Malaney, P., Metallo, S. J., Pathak, R. R., & Joerger, A. C. (2014) · Chemical Reviews · doi:10.1021/cr400713r · Cited by 288
Smith, M. C., & Gestwicki, J. E. (2012) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2012.10 · Cited by 286
Druggable pockets and binding site centric chemical space: a paradigm shift in drug discovery
Pérot, S., Sperandio, O., Miteva, M. A., Camproux, A.-C., & Villoutreix, B. O. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.05.015 · Cited by 276
Protein stability: a crystallographer's perspective
Deller, M. C., Kong, L., & Rupp, B. (2016) · Acta Crystallographica Section F Structural Biology Communications · doi:10.1107/s2053230x15024619 · Cited by 276
Nuclear receptor coregulators: modulators of pathology and therapeutic targets
Lonard, D. M., & O'Malley, B. W. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.100 · Cited by 272
Chemical Space of DNA-Encoded Libraries: Miniperspective
Franzini, R. M., & Randolph, C. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01874 · Cited by 271
Cimermancic, P., Weinkam, P., Rettenmaier, T. J., Bichmann, L., Keedy, D. A., Woldeyes, R. A., Schneidman-Duhovny, D., Demerdash, O. N., Mitchell, J. C., Wells, J. A., et al. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.01.029 · Cited by 268
Self-citationLagorce, D., Douguet, D., Miteva, M. A., & Villoutreix, B. O. (2017) · Scientific Reports · doi:10.1038/srep46277 · Cited by 266
Inhibition of protein–protein interactions using designed molecules
J. Wilson, A. (2009) · Chemical Society Reviews · doi:10.1039/b807197g · Cited by 262
A small molecule HIF-1α stabilizer that accelerates diabetic wound healing
Li, G., Ko, C.-N., Li, D., Yang, C., Wang, W., Yang, G.-J., Di Primo, C., Wong, V. K. W., Xiang, Y., Lin, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23448-7 · Cited by 261
Targeting Protein–Protein Interactions for Therapeutic Intervention: A Challenge for the Future
Zinzalla, G., & Thurston, D. E. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.12 · Cited by 260
ProteinsPlus: a web portal for structure analysis of macromolecules
Fährrolfes, R., Bietz, S., Flachsenberg, F., Meyder, A., Nittinger, E., Otto, T., Volkamer, A., & Rarey, M. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx333 · Cited by 260
Interfacial inhibitors: targeting macromolecular complexes
Pommier, Y., & Marchand, C. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3404 · Cited by 259
Introduction to Fragment-Based Drug Discovery
Erlanson, D. A. (2011) · Topics in Current Chemistry · doi:10.1007/128_2011_180 · Cited by 259
Getting pharmaceutical R&D back on target
Bunnage, M. E. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.581 · Cited by 258
Davies, D. R., Gelinas, A. D., Zhang, C., Rohloff, J. C., Carter, J. D., O’Connell, D., Waugh, S. M., Wolk, S. K., Mayfield, W. S., Burgin, A. B., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213933109 · Cited by 256
Ohoka, N., Okuhira, K., Ito, M., Nagai, K., Shibata, N., Hattori, T., Ujikawa, O., Shimokawa, K., Sano, O., Koyama, R., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.768853 · Cited by 240
“However, there are many pathogenic proteins without enzymatic activity to which pharmacological inhibitors can hardly be developed (2, 3).”
BackgroundBulatov, E., & Ciulli, A. (2015) · Biochemical Journal · doi:10.1042/bj20141450 · Cited by 237
Structural Biology and Drug Discovery of Difficult Targets: The Limits of Ligandability
Surade, S., & Blundell, T. L. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.12.013 · Cited by 230
PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery
Gu, S., Cui, D., Chen, X., Xiong, X., & Zhao, Y. (2018) · BioEssays · doi:10.1002/bies.201700247 · Cited by 231
Morelli, X., Bourgeas, R., & Roche, P. (2011) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2011.05.024 · Cited by 223
Bauer, M. R., Ibrahim, T. M., Vogel, S. M., & Boeckler, F. M. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci400115b · Cited by 200
Targeting Protein-Protein Interaction by Small Molecules
Jin, L., Wang, W., & Fang, G. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-140028 · Cited by 195
Arkin, M. R., & Whitty, A. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.05.125 · Cited by 190
Fang, L., Zhu, Q., Neuenschwander, M., Specker, E., Wulf-Goldenberg, A., Weis, W. I., von Kries, J. P., & Birchmeier, W. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1519 · Cited by 190
Systematic Analysis of Helical Protein Interfaces Reveals Targets for Synthetic Inhibitors
Jochim, A. L., & Arora, P. S. (2010) · ACS Chemical Biology · doi:10.1021/cb1001747 · Cited by 191
Tanada, M., Tamiya, M., Matsuo, A., Chiyoda, A., Takano, K., Ito, T., Irie, M., Kotake, T., Takeyama, R., Kawada, H., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c03886 · Cited by 188
Miranda, E., Nordgren, I. K., Male, A. L., Lawrence, C. E., Hoakwie, F., Cuda, F., Court, W., Fox, K. R., Townsend, P. A., Packham, G. K., et al. (2013) · Journal of the American Chemical Society · doi:10.1021/ja402993u · Cited by 185
Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma
Cardenas, M. G., Yu, W., Beguelin, W., Teater, M. R., Geng, H., Goldstein, R. L., Oswald, E., Hatzi, K., Yang, S.-N., Cohen, J., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85795 · Cited by 176
State-of-the-art strategies for targeting protein–protein interactions by small-molecule inhibitors
Sheng, C., Dong, G., Miao, Z., Zhang, W., & Wang, W. (2015) · Chemical Society Reviews · doi:10.1039/c5cs00252d · Cited by 165
London, N., Raveh, B., Movshovitz‐Attias, D., & Schueler‐Furman, O. (2010) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.22785 · Cited by 164
Metadata
- Authors
- Wells, J. A., & McClendon, C. L.
- Venue
- Nature
- Published
- 2007-12
- Volume
- 450
- Issue
- 7172
- Pages
- 1001-1009
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2056169996
- Cited by
- 1,960
- References
- 98
- FWCI
- 117.99
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.